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Restoring the balance: The Patentability of DNA-related 
Technology in the USA and Europe 
 
by Timo Minssen∗  
 
Scholarship speech prepared for the AWAPATENT Foundation for the Promotion of Scientific 
Research in the Area of Intellectual Property Rights, Operaterassen Stockholm, Jan. 27th, 2009  
 
 
Distinguished Guests, 
Esteemed clients, partners and employees from AWAPATENT, 
Ladies and Gentlemen, 
 
 
Let me begin with my little speech by emphasizing my severe gratefulness for the 
very generous grant I received from the AWAPATENT Research Foundation, 
which currently helps me through the very last stages of my research project 
prior to its publication. I feel further very much honored to have been invited to 
this wonderful event and to have been given the opportunity to deliver a brief 
speech on the topic of my PhD thesis in front of such an distinguished audience. 
 
 
Since I will have to follow a rather strict time-scheme I will now turn directly to 
the very reason for which I am standing here, and that is my nearly completed 
PhD thesis. On the first pages of my thesis you will find the following famous 
quote by Thomas Stearns Eliot: 
 
“We shall not cease from exploration. And the end of all our exploring will be to arrive 
where we started, and know the place for the first time.”    
 
Bearing this sophisticated quote in mind let me first elucidate the starting point 
of my little academic endeavor and describe the questions that I had to face.  
 
On 7 March 1953 the two young scientists, James Watson and Francis Crick, 
announced to fellow patrons of the Eagle pub in Cambridge that they had found 
“the secret of life”. Only a few weeks later, on 25 April 1953, they published an 
article in the famous Nature magazine and announced: 
 
 “We wish to suggest a structure for the salt of deoxyribose nucleic acid (D.N.A). This structure has 
novel features which are of considerable biological interest.”   
 
The short article is a brilliant example of clarity, precision and British 
understatement. What Watson and Crick actually proposed was the winding 
double helix structure of DNA, which immediately suggested how DNA would 
replicate itself. Less than 900 words later they concluded on the same page with 
the simple sentence: 
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 “It has not escaped our notice that the specific pairing we have postulated immediately suggests a 
possible copying mechanism for the genetic material.”1  
 
Their proposed model had great beauty and simplicity. However, most significant 
was that it fitted to the experimental data available. Thus, it did not take long 
until the scientific community accepted the model as being correct and a true 
breakthrough.2 While this paper can be regarded as the first step into a new era 
of genetics which in 1962 was rightfully awarded with a Nobel Prize,3 more than 
50 years later DNA related technology is still at the centre of public debate.  
 
On the one hand, the spectacular development of DNA related sciences during 
the last decades led to a technological and medical revolution. Due to the far 
reaching possibilities connected to this technology, it is the focus of many people’s 
interest and one source of the hope that one day we will find cures for many 
terrible illnesses. One has only to take a look on the more recent Nobelprizes that 
have been awarded in the new millennium, to get an understanding of the 
immense impact that modern DNA-related technology has had and presumably 
will continue to have on the development of pharmaceuticals and other 
industrially useful products.4 Accordingly, DNA related science has become a 
highly important economic factor in global business and research.  
 
On the other hand, the public has been made much more concerned about the 
level of knowledge about the human blueprint and how it is applied and 
commercialized. The debates are highly emotional and raise numerous complex 
socio-ethical, economic scientific and legal questions. At the same time, these 
discussions must continuously adapt to the rapidly evolving technology which is 
generating breathtaking novel insights about the previously unforeseen 
complexity of DNA molecules and proteins, the uses they can be applied for, and 
the various processes they are involved in. Future policies will e.g. have to 
consider new nanotechnological applications and developments, as well as 
complicated epigenetic mechanisms that were shown to play an important role in 
gene-expression and protein synthesis.5 
                                                 
1 J.D. Watson & F.H.C. Crick, Molecular Structure of Nucleic Acids, in: Nature No. 4356, p. 737 
(April 25th 1953). 
2 Cf. Carina Dennis and Richard Gallagher (ed.), The Human Genome (Palgrave 2001), at 16. 
3 See: The Nobel Prize in Physiology or Medicine 1962, which was awarded to Dr. Francis Crick, 
Dr. James Watson, and Dr. Maurice Wilkins "for their discoveries concerning the molecular 
structure of nucleic acids and its significance for information transfer in living material", more 
information is available at:  http://nobelprize.org/nobel_prizes/medicine/laureates/1962/ (last visit: 
October, 23rd, 2008). 
4 For example: Among the eighteen Nobel Prizes that were awarded from 2000 to 2008 in the 
categories Physiology or Medicine (1) and Chemistry (2), at least twelve achievements were 
directly or indirectly concerned with, or based on, DNA and protein related processes and 
phenomenons. More information is available at: http://nobelprize.org/nobel_prizes/lists/2008.html 
(last visit: November, 1st, 2008). 
5 For further information, see e.g. Jeremy Moore, Scientists develop new, more sensitive 
nanotechnology test for chemical DNA modifications (Sept. 24th, 2008), available at: 
http://www.innovations-
report.de/html/berichte/biowissenschaften_chemie/scientists_develop_sensitive_nanotechnology_t
est_118943.html, Wiley-Blackwell, Nano-Softball made of DNA (April, 1st 2008), available at:  
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Unsurprisingly, the debate is particularly fierce with regard to the question of 
whether it should be possible to patent the results of DNA–related technology, be 
it in the form of novel DNA sequences and the uses for those sequences or in the 
form of the proteins that are encoded by such sequences. In the often heated 
discussions there are, by and large, two diametrically conflicting schools of 
thoughts: 
 
Some people believe for multiple different reasons that DNA, an in particular 
human DNA, is much more than a mere chemical structure. They argue that 
DNA is the embodiment of the code of life and that it should be regarded as part 
of the common heritage of mankind. They believe that any form of patenting 
DNA, or of the natural processes it is involved in, is utterly wrong. Some patent 
opponents go even further and argue for a regime that would also ban the 
patents on any kind of proteins.6  
 
Others, i.e. in particular the life science industry, argue that DNA and proteins 
are simply chemical compounds, albeit complex ones. Thus they take the view 
that it, at least in principle, should be possible to grant patents on isolated DNA 
sequences7 and the proteins that are encoded by it. In the past years, legislators 
and patent authorities have basically followed this line of thinking. As a 
consequence, both in Europe and in the US the grant of DNA related patents and 
their encoded products had become routine.  
 
While it seems to be extremely difficult, if not impossible, to find a compromise 
between these fundamentally different views, the purpose of my thesis is, 
however, primarily related to a third area where diverging opinions can be 
detected. Recognizing the immense importance of patents for technology transfer 
and, in particular, for the risky, extremely time-consuming and incredibly 
expensive development of “top quality” pharmaceutical products, my research 
focuses on the fierce discussions among those who principally support patents on 
DNA -related technology over particular threshold-requirements for receiving 
such patents, the appropriate scope of its protection and its exclusionary effects. 
Among other things it is feared that too lenient standards for the granting of 
patent rights in upstream research might lead to patent thickets caused by far 
too many trivial patents and royalty stacking which - in combination with the 
                                                                                                                                                        
http://www.firstscience.com/home/news/breaking-news-all-topics/nano-softball-made-of-dna-page-
2-1_45564.html (last visit: November 1st, 2008);  Rothstein, Mark A., Cai, Yu Cai and Marchant, 
Gary E., The Ghost in Our Genes: Legal and Ethical Implications of Epigenetics (June 3, 2008). 
available at SSRN: http://ssrn.com/abstract=1140443 . Interestingly, the Nobel Prize in 
Physiology or Medicine which was awarded to Andrew Z. Fire and Craig C. Mello in 2006 "for 
their discovery of RNA interference - gene silencing by double-stranded RNA" was concerned with 
one of the epigenetic mechanisms which now is also becoming a major issue in patent law. More 
information is available at: http://nobelprize.org/nobel_prizes/medicine/laureates/2006/ (last visit: 
November 1st, 2008). 
6 Particularly the so called “product and process of nature doctrines” could be mentioned in that 
context, which can still be found in both the European and the US debate. 
7 i.e. new, inventive, useful and well described DNA sequences that were isolated from their 
natural environment  by human intervention. 
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specific market behavior of some patent holders - ultimately will have a negative 
effect on beneficial research and downstream product development (Tragedy of 
the anticommons). (Potential) anticommons problems, have been reported in the 
literature in a broad variety of novel technical fields relating to technologies such 
as climate-related technology computer-related technology, nanotechnology, and 
in particular biotechnology and diagnostic testing.8 Quite recently even the 
preliminary EC Commission’s report of the Pharma Sector inquiry has pointed 
towards this potential problem (although the conclusions that were drawn are 
ferociously debated). 9  
 
Related to this debate is also the discussion concerning the proper scope of 
protection that should be conferred to DNA-related patents. In particular, the 
specific issue of so called full product patents on DNA- and protein sequences 
whose functions have not fully been understood is in the light of novel scientific 
insights heavily discussed. This debate is especially fierce in the context of 
patents on human DNA sequences and has pursuant to political and judicial 
pressure led to quite drastic, incoherent legal responses. As a matter of fact, some 
EC Member states have now introduced various legislations that only allow 
purpose bound product protection for (human) DNA sequences and, in some 
countries, even for proteins. This legislative activity has unfortunately led to a 
range of legal and practical problems. Additionally, it seems not to have taken 
due account of recent data which reveals that even in patent systems which still 
allow for full product protection, the patent activity is thanks to scientific 
developments and a more stringent application of the traditional patentability 
requirements, already shifting from the patenting of isolated compounds to the 
patenting of novel uses and methods that have been developed with such 
sequences.  
 
Yet, it should also be emphasized that even more robust and narrow patent 
claims may in the course of technological advances still lead to patent thickets 
                                                 
8 Compare F.M Scherer, The Economics of Human Gene Patents, 77 Academic Medicine (2002), at 
1363 (arguing that this problem is analogous to conditions on the Rhine River durng the 18th 
century), M. A. Heller and R. S. Eisenberg, Can Patents Deter Innovation? The Anticommons in 
Biomedical Research, Science 1 May 1998: Vol. 280. no. 5364, pp. 698 – 701. Several authors have 
reported potential anticommons problems relating to diagnostic testing via genes, e.g.  B. 
Verbeure et. al, Patent pools and diagnostic testing TRENDS in Biotechnology Vol. 24 No. 3 
March 2006 115-120. M. M. Hopkins et.al, DNA patenting: the end of an era? Nature 
Biotechnology 25, 185 - 187 (2007) who do not see any present signs of anticommons but warn 
that such may come. A similar conclusion on software is found in J. Bessen and M. J. Meurer, 
Patent Failure, 2008 pp. 190-193. The 2003 FTC Report, To Promote Innovation: The Proper 
Balance of Competition and Patent Law and Policy, p. 6 (see also the 2007 FTC report). See 
further Rubinfeld, D. L. and Maness, R., The Strategic Use of Patents: Implication for Antitrust 
pp. 85-102 in F. Lévêque and H. Shelanski, Antitrust, Patents and Copyright- EU and US 
Perspectives, 2005, p. 88. 
9 See Commission (2008b), Pharmaceutical Sector Inquiry – Preliminary Report, DG Competition 
Staff Working Paper 28.11.2008. At present a lot of criticism is presented at the Commission’s 
homepage. It remains to be seen how much of this criticism will be reflected in the final report 
which can be expected before next summer. Se in particular the speech by Rt. Hon. Sir Robin 
Jacob, which is available at: 
http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/index.html (last visit January 
19th 2009). 
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and anticommons problems.10 It is thus clear that this issue requires further 
monitoring taking into account novel insights from economic studies and 
scientific developments. 
 
My thesis therefore takes a similar position as SOU 2008:20. In the absence of 
any further evidence and in the face of the more recent developments, I think 
that there is at present no immediate need to introduce such radical steps like a 
categorical purpose bound product protection into patent legislation. Yet, the 
situation should be monitored. Moreover, I believe that (pro-)active measure that 
might have to be taken should also carefully consider more flexible post- grant 
solution models before introducing fundamental changes into the patent 
system.11 
 
What I have described so far might give the false impression that I am simply 
claiming that the opposition and the radical legislative reaction was merely 
caused by a lack of knowledge of the existing checks and balances already 
present in the patent system. The present situation is, however, far more 
complicated: 
 
In a time were the complexity of DNA expression and application became more 
and more apparent, while the USPTO continued to regularly grant full product 
patents on DNA sequences which could arguably be isolated with a reasonable 
expectation of success by applying routine methods, in a time where US patents 
were granted on methods of swinging a swing and a crust-less peanut butter 
sandwhich, in a time where the patent offices on both sides of the Atlantic are 
still facing several hundred thousand patent applications per year while a 
considerable backlock of patent applications still exists, and in a time were 
numerous so called patent trolls are lurking under the bridge, waiting for creative 
developers of new products to be locked in a market before threatening them with 
their trivial, undeveloped patents in order to seek rent either through licensing 
or litigation,  I think it cannot be ignored that the current criticism of the 
patentability rules was indeed also raising some serious questions about the 
proper interpretation of the patentability requirements and about the procedural 
system in which these patents are granted and enforced.  
 
More specifically, my thesis therefore investigated how the European and US 
Patent systems interpret and apply the traditional basic patentability 
                                                 
10  M. M. Hopkins et.al,  DNA patenting: the end of an era?, Nature Biotechnology 25, 185 - 187 
(2007) at p. 187: “For now, we contend that the potential negative impact of the many patent 
applications filed during the build up to the publication of the Human Genome Project may be 
less than many have feared. However, we add a caveat. Although the increasing tendency of 
patent offices to grant patents claiming DNA with narrower scope and more robust claims is to be 
welcomed, assignees in our study indicated that they are responding by filing patents claiming 
splice variants and SNPs. The possibility of a corresponding upswing in the number of DNA 
patents entailing narrower claims could reopen concerns about an anticommons effect. Although 
we acknowledge that there is as yet little evidence to go on,, such a prospect is best countered by 
vigilance in the application of the criteria for patentability, particularly inventiveness, by patent 
offices." 
11 See further below. 
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requirements vis-à-vis DNA related inventions.  Besides describing and 
evaluating the de lata situation through analysis of the most recent case law and 
regulations, this thesis also presents de lege ferenda proposals. In that regard 
special attention has been given to the above described debate over the so called 
“Tragedy of the Anticommons” . Recognizing that the gravity of “anticommons” 
scenarios is difficult to prove12  and also depends on a variety of “pre-grant“ and 
“post-grant” factors that fall outside the scope of the analysis, my thesis 
highlights the importance of a well balanced and stringent application of the 
central patentability requirements in order to achieve enforceable, well defined 
“high quality” patents which may either forestall or moderate (potential) 
anticommons situations, or at least provide a sound basis for more 
comprehensive solution models that try to tackle such situations at the post 
grant level.      
 
So, what is a “high quality” patent and how can we achieve such “high quality” 
patents?  In my view one of the basic features of a “high quality patent” is that it 
is enforceable, well defined and – what is most important – that it corresponds to 
the actual technical contribution that the inventor as provided to the state of the 
art. Particularly, in the pioneering phase of emerging technologies, I believe that 
this must in some cases allow the strong protection that can be achieved by 
granting full product protection – although as technology matures I think that 
such strong/broad protection should be increasingly limited to very exceptional 
cases. I also think that both in the US and Europe, a thorough examination of 
each case on its own merits should (in combination with flexible post-grant 
solution mechanisms) indeed achieve the goal of granting (and enforcing) claims 
of a format and scope which corresponds to the actual technical contribution to 
the state of the art by the patent application/patent. This should in the most 
cases alleviate the effects of what is perceived by some as a far too liberal patent 
system granting excessively broad protection to DNA related inventions.13 
 
By scrutinizing systematically how the US and European Patent offices and 
courts interpret and apply the basic patentability criteria with regard to DNA 
related inventions, my thesis demonstrates that the US and European patent 
systems have reacted to the challenges and are already on the right track - 
although many problems still remain. A closer look on the interpretation and 
effect of the novelty requirement reveals for example that the publication of 
                                                 
12 Compare Holman, “The Impact of Human Gene Patents on Innovation and Access: A Survey of 
Human Gene Patent Legislation”, Berkely Center for Law and Technology”, paper 43 (2008), 
available at http://repositories.cdlib.org/bctl/lts/43 (last visit Januray 10th 2009), who warns at p. 
67, that “Without more compelling evidence of an overwhelming negative impact in contexts that 
are critical to the public good, there is no adequate justification for rushing into a radical 
legislative fix that might have substantial unintended negative consequences.” See also Caulfield 
et al, “Evidence and anecdotes: an analysis of human gene patenting controversies”, in: Nature 
Biotechnology 24(9):1091-1094 (2006).  
13 This view is shared by Galligani in his contribution to the 13. symposium of European patent 
judges in Thesaloniki 12. – 16. September 2006, available in De., En. and Fr.,  special edition 
2/2007 OJ EPA., 148 – 16 (156); available at:  <http://www.european-patent-
office.org/epo/pubs/oj007/04_07/special_edition_2_judges_symposium.pdf> (last visit March, 11th 
2007). 
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almost all human DNA sequence information by the Human Genome Project, and 
the increasing volume of various protein data banks has made it much more 
difficult to establish novelty of a sequence as such. Moreover, the mere fact that 
the methods for identifying and isolating sequences have become increasingly 
routine has led to a situation, where it has become much more difficult to fulfill 
the European inventive step requirement if the sequence in question had not 
been extraordinarily difficult to find or had surprising properties. After the US 
Supreme Court had delivered its famous KSR decision in 2007 and in particular 
after following the USPTO decision in Ex parte Kubin (which is now In re Kubin 
and pending at the CAFC – oral proceedings were held only a couple of days ago), 
it has become equally difficult to fulfill the US nonobviousness criterion if their 
was a reasonable expectation of success to arrive at the invention.  
 
Moreover, recent case law and examinations guidelines  in the US and Europe 
have shown that the information (be it information based on in silicio or wet –
biology experiments) which is delivered in connection with the patent application 
must be of such a quality that it is made at least plausible that a solution to the 
underlying problem and a profitable use had been found and disclosed, otherwise 
this can result either in a objection based on lack of inventive step (see for 
example, T 1329/04 where it was found that no plausible solution to the 
underlying technical problem was disclosed), or lack of industrial application (see 
for example T 870/04 and in In re Fisher14, where no profitable and immediate 
use for the “real world” or industry was found to be disclosed – see also recent UK 
cases15).  
 
Also the thresholds for the sufficient disclosure requirement have been 
recently heightened both in Europe and in the US. It will for example no longer 
be sufficient to give a vague indication of a possible medical use of compounds 
which would still have to be identified. The EPO would consider this to amount to 
a fundamental, incurable insufficiency of disclosure (T609/02). Once again, 
similar developments can be detected in the US, where already the KSR inspired 
USPTO decision in Ex Parte Kubin has been triggering “early” (i.e. without 
waiting for In re Kubin16) changes in the US examination guidelines for the 
written description requirement that point towards a more strict, possession 
based line of case law. In that respect the In re Kubin decision that we can expect 
by the CAFC within the next 90 days, will be of tremendous importance for the 
biotech industry. Unfortunately, I will not have the time to go further into the 
details here. 
 
To sum it up, I think that my research shows that the checks and balances 
already existing within the current patent system can tackle many problems if 
they are properly and strictly applied. In the face of vigorous attacks of the 
                                                 
14 Cf. In re Fisher, 421 F.3d 1365 (Fed. Cir. 2005). 
15 See eg. Eli Lilly & Company v. Human Genome Sciences, Inc. EWHC 1903 [31 July 2008], 
available at: http://www.bailii.org/ew/cases/EWHC/Patents/2008/1903.pdf   (last visit August, 1st  
2008). 
16 In re Kubin, CAFC App. No. 2008-1184, Ex parte Kubin, 2007 WL 2070495 (PTO Bd. App.& 
Int. 2007) (Linck, AP). 
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patent system it will therefore be utterly important to communicate these 
positive effects and the ratio of the patent system to the public and the research 
community.  
 
In that regard it should also be underlined that the system should be well 
balanced, and, in particular, that not everything should be and can be solved by 
an increasingly strict application of the patentability rules, without risking to 
hamper an effective innovation system that builds on incremental scientific steps 
(with regard to the research tool issue), legal certainty, as well as practicability 
and predictability. 
 
I believe that sustainable solutions can only be achieved if those changes in 
patent law & procedure that are absolutely indispensable are accompanied by 
changes on the post grant level, taking into consideration a more coherent 
interpretation of research exemptions, competition law, procedural changes in 
patent litigation, a more flexible doctrine of equivalence and more 
elaborated/uniform guidelines on patent pools, clearing houses or other private 
ordering/licensing solutions.17 (yet, I think that compulsory licensing should 
remain a last resort, which should only be taken into consideration in extreme 
situations). 
 
Numerous recent patent related judgments by US and European courts18 that 
have stipulated novel patent examination guidelines and decisions by the patent 
offices, as well as various legislative reform initiatives, indicate that decision 
makers on both sides of the Atlantic seem to share this view and have started to 
address the numerous challenges that lay ahead of us accordingly.   
 
If these changes are conducted carefully and acknowledge and respect the 
importance of a well balanced patent system, I think that modifications of the 
                                                 
17 With regard to ordering solutions compare e.g. F. Scott Kieff and T. A. Paredes  Engineering a 
Deal: Toward a Private Ordering Solution to the Anticommons Problem  Stanford Law and 
Economics Olin Working Paper No. 330 , Washington University School of Law Working Paper 
No. 06-12-01 (available at SSRN=948468) at p. 2. 
18 As for the US Supreme Court see for example Quanta Computer Inc. v. LG Electronics Inc., 128 
S.Ct. 2109 (2008) [exhaustions doctrine], KSR International Co. v. Teleflex Inc., 82 USPQ2d 1385, 
see also 38 IIC 735 (2007) [non-obviousness]; MedImmune, Inc. v. Genentech, Inc., 81 USPQ2d 
1225 (2007) [jurisdiction in declaratory judgment actions] and Microsoft Corp. v. AT&T Corp., 82 
USPQ2d 1400 (2007) [applicability of the US Patent Act with regard to foreign duplication of 
software]. See also the 2006 decisions in eBay Inc. et alia v. MercExchange, L.L.C., 78 USPQ2d 
1577 (2006) [injunctive relief in patent infringement suits], and Labcorp v. Metabolite, 79 
USPQ2d 1065 (2006) [patentable subject matter-dismissed as improvidently granted], as well as 
the 2005 decision in Merck KGaA v. Integra Lifesciences I, Ltd.,  545 U.S. 193 (2005) 
[interpretation of 35 U.S.C. § 271 (e) (1)], which was followed by several interesting CAFC 
decisions. See also further extremely important decisions which might end up in the Supreme 
Court, such as Bilski v. Doll, Supreme Court No. 08-964, and _F.3d_ (Fed. Cir. 2008) (en banc) 
(Michel, C.J.) [patent eligibility]. Compare in addition the recent antitrust judgments in FTC v. 
Rambus, Supreme Court No. 08-694, Rambus v. FTC, 522 F.3d 456 (D.C. Cir. 2008) (Williams, J.) 
[SSO Antitrust Petition]. As for European competition law related decisions see in particular C T-
201/04 Microsoft Corp. v EC Commission, C-498/06 to C-478/06 GlaxoSmithKline andCase 
COMP/A. 37.507/F3 AstraZeneca. 
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legal rules on the post-grant level might give us an efficient “surgical” tool to 
carefully counterbalance the potential negative effects that patents might have. 
 
Ladies and gentlemen, this brings me to the end of what I wanted to say to you. 
Let me now conclude by returning to my starting point and that is the quote by 
T.S. Eliot: 
 
“We shall not cease from exploration. And the end of all our exploring will be to arrive 
where we started, and know the place for the first time.”  
 
So, how does it feel now, standing there? Do I really know the place for the first 
time? Well, to some extend I do. I could point out – or give at least a qualified 
prediction on – various negative and positive effects that would result from 
various interpretations of the basic patentability requirements with regard to 
DNA-related technology. I even achieved some kind of understanding of how the 
various issues that are raised on the pre- and post-grant level are related which 
each other, and I learned more about the delicate balance between competition 
law and patent law, although I only focused on the latter. But what is more 
important in that context is that I do know more about, what I do not know.  
 
Having reached the end of my PhD journey I became even more fascinated over 
the amazing complexity not only of the technology, but also of the legal 
framework and the socio-economic impact of the legal rules and the practice that 
tries to regulate its commercialization in a utilitaristic way. I feel like I managed 
to put one or two pieces of a puzzle into the right place, although the optimal 
solution might consist of at least 100 pieces. At the same time, I believe that this 
is going to be an eternal puzzle and that perhaps the complete and perfect 
solution will never be revealed, since the shape of the perfect solution is 
continuously shifting in the face of technological, economic and sociological 
changes.  
 
In that regard, it is perhaps better to speak of a calibration or weighing process, 
where the ultimate goal is to find a dynamic balance between competing and 
interacting values, such as access to technology and health care, dynamic and 
static competition, as well as the goal to provide incentives for research through 
securing the return of investments in order to achieve the greatest public good. It 
is then my hope that interdisciplinary research will develop its channels of 
communication and finally bring together academics and practitioners from 
various scientific fields in order to refine the system both on the pre- and post-
grant level. This might make it possible to at least narrow down the amplitude in 
which the scale19 should be allowed to swing and thereby to reduce the costs of 
the system and increase its benefits.    
 
How this could exactly be achieved would be the ultimate finding of any related 
PhD thesis which would probably deserve a price equal to a Nobel price. The 
ultimate finding of my thesis is far less ambitious, if not to say humble, and can 
                                                 
19 more commonly it is often referred to a pendulum. 
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for some reason be detected in the great majority of academic findings. It boils 
down to this: 
 
  “We need more research” 
 
Thank you very much for your attention. 
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